Lincoln Pharmaceuticals — 360° view

Lincoln Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹191 crore and net profit of ₹20 crore for the September 2026 quarter.

Lincoln Pharmaceuticals (NSE: LINCOLN) closed at ₹511.90 on 20 Nov 2026, down 4.0% over the past year. Its market capitalisation is ₹1,025 crore and it trades at 10.6 times earnings.

Share price
₹511.90 (20 Nov 2026)
Market cap
₹1,025 Cr (20 Nov 2026)
P/E
10.58 (20 Nov 2026)
Revenue
₹191 Cr (September 2026 quarter)
Net profit
₹20 Cr (September 2026 quarter)
ROCE
16.0% (FY26)
ROE
12.0% (FY26)
Book value
₹405 (FY26)
Dividend yield
0.35% (last 12 months to 20 Nov 2026)
52-week high / low
₹770.00 / ₹440.00 (20 Nov 2026)
1-year return
-4.0% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: LINCOLN

Incorporated in 1979, Lincoln Pharmaceuticals Ltd is in the business of manufacturing and trading of pharmaceutical products

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.